Neuroradiology Roundup: New PET Tracer, WMH Risk Factor, and Amyloid PET Software

FDA-approved floretyrosine F18 PET targets glioma imaging. A study suggests that diabetes and low bone density on chest CT may accelerate brain white matter hyperintensity accumulation. FDA-cleared software enhances amyloid PET via structural MRI.

• The FDA has approved floretyrosine F18, a PET agent for imaging glioma.
• A retrospective study linked diabetes and low bone mineral density on chest CT to faster accumulation of white matter hyperintensities on brain MRI.
• Newly FDA-cleared software uses structural MRI to improve amyloid PET image quality.

Automated summary

RadPigeon summaries are original and for information only. They are not clinical advice.